Dan Mendelson is Founder and former CEO of Avalere Health, a vibrant community of innovative thinkers dedicated to solving the challenges of the healthcare system.

  He is also Operating Partner at Welsh Carson, a private equity firm focused on healthcare and technology investments.  Prior to founding Avalere in 2000, Dan served as Associate Director for Health at the Office of Management and Budget in the Clinton White House where he was responsible for the full healthcare portfolio including Medicare, Medicaid, NIH, CDC, and FDA.  

Dan presently serves on the boards of Champions Oncology (CSBR), Centrexion Corporation, and Audacious Inquiry.  He is Adjunct Professor at Georgetown University’s McDonough School of Business, and a founding member of Guidon Partners, an investment management group.  Dan also serves on advisory boards for the Alliance for Health Policy, the Duke Margolis Center, and Faster Cures.  He previously served on the boards of Coventry Healthcare (CVTY, sold to Aetna in 2013), PharMerica (PMC, sold to KKR in 2017), and HMS holdings (HMSY).

Dan is a leading national thought leader on healthcare business issues, is often quoted in the press, and enjoys speaking.  He has also published widely in peer-reviewed and professional journals on health information technology, the costs of disease, hospital costs and operations, physician payment, the economics of managed care, and medical malpractice. He holds a BA from Oberlin College, and an MPP from the Kennedy School at Harvard University.

Authored Content

The COVID-19 pandemic and a summer of focus on racial justice has finally begun to intensify government interest in reducing racial disparities in healthcare. Understanding that healthcare providers and systems tend to respond to the economic incentives that are presented to them, current government decisions on payment options around renal dialysis present an important test case for the Trump Administration.

Tune into our first episode of the Avalere Health Essential Voice: 2020 Election series. In this segment, our experts discuss the healthcare disparity issues at the forefront of the 2020 election and which healthcare topics to watch for at the Democratic National Convention.

In the first episode of the 2020 Election with Avalere series, Avalere experts discuss the healthcare disparity issues at the forefront of the 2020 election and which healthcare topics to watch at the Democratic National Convention.

Avalere’s 2020 Election series started with our experts covering the current state of play in the 2020 election and the role of healthcare between now and November.

As Medicare Advantage enrollment grows and benefits continue to evolve, beneficiaries must keep pace with these changes and investigate plan options amidst current healthcare debates.

Health plans today have a range of strategic opportunities that align well with emerging policy themes for 2020.

The Centers for Medicare & Medicaid Services (CMS) is currently reviewing a new payment rule, which could impact coverage of innovative procedures like transcatheter aortic valve replacement for the treatment of severe aortic stenosis.

As former federal officials, Dan Troy, David Beier, and I share our perspectives on the call by former FDA officials representing both political parties to make the FDA an independent agency separate from its parent, HHS.

Today continues a steady diet of healthcare cost hearings with committees on both sides of Capitol Hill digging into the issue.

The transition from old-guard payer to wellness company is underway–and moving rapidly.

Tune in to hear the first episode in our 3-part series covering the mid-term elections and potential implications on health policy. Avalere expert, Chris Sloan, discusses potential implications of the mid-term elections on health policy. To kick off the series Avalere Founder, Dan Mendelson, covers pre-existing conditions.

New analysis from Avalere finds that 102 million individuals, not enrolled in major public programs like Medicaid or Medicare, have a pre-existing medical condition and could therefore face higher premiums or significant out-of-pocket costs if the ACA’s pre-existing condition protections were repealed.

New research from Avalere finds that Medicare Advantage (MA) beneficiaries with hypertension, hyperlipidemia, and diabetes experienced significantly fewer inpatient stays and emergency room visits relative to those in traditional fee-for-service (FFS) Medicare.

Patient out-of-pocket costs continue to grow despite policies to increase affordability for beneficiaries.

Avalere's founder and president, Dan Mendelson, recently sat down with Senior Housing News editors to discuss opportunities for senior living providers to leverage data to facilitate synergistic partnerships with payers.

New research from Avalere finds Medicare beneficiaries are spending fewer days in skilled nursing facilities (SNFs) since 2009 on a per capita basis.

New analysis from Avalere finds that the proposed rule on association health plans (AHPs) is projected to lead to 3.2M enrollees shifting out of the Affordable Care Act's (ACA) individual and small group markets into AHPs by 2022.

Today, the Trump Administration released its budget for fiscal year 2019 (FY 2019).

Avalere experts provide their insights on what the impact of coverage gap discount changes in budget agreement.

Kenny Kan has joined the Avalere team leading the firm's actuarial analytics. Prior to joining Avalere, Kan served as the Chief Actuary at Humana and CareFirst.

Gillian Wollett, Senior Vice President of Avalere’s FDA & Regulatory Policy team, recently published “A ‘Global Reference’ Comparator for Biosimilar Development” in BioDrugs.

Analysis also finds that 62% of impacted facilities will experience less than a 5% reduction in Medicare Part B revenue due to the drug cuts, but 6% of applicable hospitals will experience cuts greater than 10%.

Brow was most recently regional SVP of The US Oncology Network for McKesson.

Avalere's President and Founder, Dan Mendelson, recently wrote a column about the new strategies that device manufacturers should take in this era of healthcare.

On Tuesday, June 13, Christie Teigland, PhD, will participate in a panel discussion entitled “Measuring and Reporting Social Risk Factors” as part of a dissemination meeting on the report series “Accounting for Social Risk Factors in Medicare Payment,” sponsored by the National Academies of Medicine.

Tom Kraus, who most recently served as the chief of staff at the FDA, will be joining Avalere as senior vice president.

Sean Creighton has joined the Avalere team as a vice president in the policy practice, and will be responsible for leading advisory services work tied to Medicare Advantage, risk adjustment, and related issues.

Scott Peterson, formerly Chief Information Officer at the Minnesota Department of Human Services, is joining Avalere’s Data Analytics and Development team.

Avalere will empower expanded insight and improvement in outcomes for value-based diabetes medications, using Inovalon’s data resources and advanced value-based care platforms.

Avalere Vice President, Christie Teigland, PhD, was recently appointed to the Pharmacy Quality Alliance’s (PQA) Quality Metrics Expert Panel (QMEP) for a three-year term effective January 1, 2017.

Results from a new Avalere study will be presented Thursday, October 27, at the 30th Annual North American Cystic Fibrosis Conference in Orlando, Florida.

Avalere experts predict that one-third of the country will have no exchange plan competition in 2017, leaving consumers with few options for coverage.

Data show gaps in care integration across provider settings following hospital discharges.

Wendy Everett, ScD, joins Avalere as a senior advisor.

Avalere and Inovalon recently entered into an agreement with Bristol-Meyers Squibb (BMS) to support the manufacturer's innovative initiatives using real-world outcomes data to design and test value-based contracting models. The agreement brings together Avalere's deep expertise on manufacturer and payer contract negotiation and Inovalon's significant data assets to meet the complex challenges around ensuring value and access while addressing growing healthcare costs concerns.

Christie Teigland, PhD, vice president, Advanced Analytics, recently received the Academy of Managed Care Pharmacy’s (AMCP) prestigious Platinum Award for her research entitled “Association of Socioeconomic and Clinical Factors with Rates of High-Risk Medication Use in Medicare Advantage Plans.”

Avalere and Inovalon have entered into a multi-year agreement with Kindred Healthcare, Inc., the nation’s largest provider of post-acute care (PAC) services, to deploy the power of data and analytics to engage payers. The combined solutions will result in a data-driven platform that will support Kindred in improving clinical outcomes and promoting coordinated, efficient care under new value-based payment models.

Fred Bentley, an experienced leader in payment and delivery system reform, has joined Avalere’s Center for Payment & Delivery Innovation. Fred will supplement our existing deep expertise in provider strategy and provide analytic and strategic support on issues related to care delivery.

In 2016, 2 key themes underlie much of the shift in the healthcare landscape: cost and value. Each of these elements is critical as we attempt to reduce costs by improving value across the healthcare system. Caroline Pearson, Senior Vice President, Strategy and Policy, gives a preview of what to expect.

Sheila Fifer, PhD, and Randel Richner, BSN, MPH, have joined Avalere as senior advisors.

We are excited to share with you the next phase in Avalere’s journey.

Avalere won second place in the 2nd Annual LINK Innovation Competition for its Vantage Care Positioning System (CPS).

Avalere senior vice president, Gillian Woollett, has been appointed to the U.S. Pharmacopeial Convention’s Nomenclature and Labeling Expert Committee (NLEC).

The health insurance company Aetna announced Friday it will buy rival Humana for $37 billion. The merger comes as other health insurers consider consolidating to cut costs. Read NPR's interview with our founder, Dan Mendelson.

The healthcare delivery system is one of the most complex businesses in the country.

New research from Avalere finds that despite the innovation of abuse-deterrent properties and labeling for branded opioids, Medicare Part D plan coverage for these products is declining rapidly.

Avalere Health today announced the hiring of Nancy McGee as executive vice president to head its thriving life sciences business unit.

Avalere director, Leigh Ann Bruhn, was recently named to the Academy of Managed Care Pharmacy’s (AMCP) Corporate Member Council.

Avalere director Dr. Lakshman Ramamurthy will be a panelist on the Centers for Medicare and Medicaid Services’ (CMS) Medicare Evidence Development and Coverage Advisory Committee (MEDCAC), which will meet on Tuesday, March 24.

As healthcare leaders and policymakers look to curb spending and improve quality, they should examine models like the Alternative Quality Contract (AQC), according to a new paper by Avalere.

Lisa Latts, MD, and Rick Smith join Avalere's team.

Sheahan will lead Avalere Communications, a rapidly growing group within Avalere Health that brings deep substantive and innovative strategic thinking to healthcare communications.

Avalere-Pope Woodhead collaboration a natural fit to deliver global market services

Avalere Health announced today that Lindy Hinman will be re-joining the company as senior vice president, leading its Health Plans and Managed Care Practice.

New Avalere research for The SCAN Foundation demonstrates the ROI potential of well-targeted care coordination programs supported by robust data.

New team members add depth and experience across multiple health policy issues.

Lakshman Ramamurthy, PhD, director of FDA & Regulatory Policy at Avalere Health, has been appointed by the Centers for Medicare and Medicaid (CMS) to serve as an industry representative to the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC).

This month, Avalere Health proudly joins the Health Data Consortium (HDC), an organization comprising government, private sector, and non-for-profit entities, whose goal is to improve health and healthcare by advancing the availability and innovative use of data.

In this year's Outlook, Avalere experts analyze which key events will impact your industry most, and when to start to prepare.